Macrolides and staphylococcal biofilms;Macrólidos y biopelículas estafilocócicas

Revista Espanola de Quimioterapia

Volumn 25, Issue 1, 2012, Pages 10-16

  Parra Ruiz, Jorge ^a   Vidaillac, Céline ^b,c   Rybak, Michael J ^d  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b NANCY UNIVERSITÉ   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CLARITHROMYCIN; DAPTOMYCIN; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; ROXITHROMYCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BIOFILM; BREAST ENDOPROSTHESIS; CANDIDIASIS; CATHETER INFECTION; CENTRAL VENOUS CATHETER; COCHLEA PROSTHESIS; CORONARY STENT; CORYNEBACTERIUM INFECTION; CYSTIC FIBROSIS; DEVICE INFECTION; DOSE RESPONSE; DRUG EFFICACY; DRUG PENETRATION; ENTEROCOCCAL INFECTION; GRAM NEGATIVE BACTERIUM; HEART ASSIST DEVICE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MEDICAL DEVICE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORTHOPEDIC PROSTHESIS; PERITONEAL DIALYSIS; PROGNOSIS; PROPIONIBACTERIUM; PROSTHESIS INFECTION; PROSTHETIC VALVE THROMBOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; URETHRAL CATHETER;

ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 84859637146     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37:1771-6.
2. Frank KL, Reichert EJ, Piper KE, Patel R. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 2007;5 1:888-95.
3. Jefferson KK. What drives bacteria to produce a biofilm? Fems Microbiol Lett 2004; 236:163-73.
4. Gunther F, Wabnitz GH, Stroh P, et al. Host defence against Staphylococcus aureus biofilms infection: phagocytosis of biofilms by polymorphonuclear neutrophils (PMN). Mol Immunol 2009; 46:1805-13.
5. Schommer NN, Christner M, Hentschke M, Ruckdeschel K, Aepfelbacher M, Rohde H. Staphylococcus epidermidis uses distinct mechanisms of biofilm formation to interfere with phagocytosis and activation of mouse macrophage-like cells 774A.1. Infect Immun 2011; 79:2267-76.
6. Costerton JW. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res 2005:7-11.
7. Rosenthal VD, Maki DG, Salomao R, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006; 145:582-91.
8. Lynch AS, Robertson GT. Bacterial and fungal biofilm infections. Annu Rev Med 2008; 59:415-28.
9. Cataldo MA, Petrosillo N, Cipriani M, Cauda R, Tacconelli E. Prosthetic joint infection: recent developments in diagnosis and management. J Infect 2010; 61:443-8.
10. El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29:961-7.
11. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23:14-34.
12. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805-19.
13. Moran E, Byren I, Atkins BL. The diagnosis and management of prosthetic joint infections. J Antimicrob Chemother 2010; 65 Suppl 3:iii 45-54.
14. Cobo J, Miguel LG, Euba G, et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect 2010; 17:1632-7.
15. Kobayashi H. Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995; 99:S26-S30.
16. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42:186-91.
17. Yanagihara K, Tomono K, Imamura Y, et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother 2002; 49:867-70.
18. Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 1998; 44:190-7.
19. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemoth 2004; 54:21-8.
20. Yasuda H, Ajiki Y, Koga T, Yokota T. Interaction between Clarithromycin and Biofilms Formed by Staphylococcus-Epidermidis. Antimicrob Agents Chemother 1994; 38:138-41.
21. Fujimura S, Sato T, Kikuchi T, Zaini J, Gomi K, Watanabe A. Efficacy of clarithromycin plus vancomycin in mice with implant-related infection caused by biofilm-forming Staphylococcus aureus. J Orthop Sci 2009; 14:658-61.
22. Fujimura S, Sato T, Mikami T, Kikuchi T, Gomi K, Watanabe A. Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed on titanium medical devices. Int J Antimicrob Agents 2008; 32:481-4.
23. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 2010; 54:4329-34.
24. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol 2010; 8:623-33.
25. Abee T, Kovacs AT, Kuipers OP, van der Veen S. Biofilm formation and dispersal in Gram-positive bacteria. Curr Opin Biotechnol 2011; 22:172-9.
26. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002; 295:1487.
27. Vu B, Chen M, Crawford RJ, Ivanova EP. Bacterial extracellular polysaccharides involved in biofilm formation. Molecules 2009; 14:2535-54.
28. Ryder C, Byrd M, Wozniak DJ. Role of polysaccharides in Pseudomonas aeruginosa biofilm development. Curr Opin Microbiol 2007; 10:644-8.
29. Tielen P, Rosenau F, Wilhelm S, Jaeger KE, Flemming HC, Wingender J. Extracellular enzymes affect biofilm formation of mucoid Pseudomonas aeruginosa. Microbiology 2010; 156:2239-52.
30. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol 2008; 322:207-28.
31. O'gara JP. Ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. Fems Microbiol Lett 2007; 270:179-88.
32. Palmer J, Flint S, Brooks J. Bacterial cell attachment, the beginning of a biofilm. J Ind Microbiol Biotechnol 2007; 34:577-88.
33. Dunne WM, Jr. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev 2002; 15:155-66.
34. Christner M, Franke GC, Schommer NN, et al. The giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectin. Mol Microbiol 2010; 75:187-207.
35. Fey PD, Olson ME. Current concepts in biofilm formation of Staphylococcus epidermidis. Future Microbiol 2010; 5:917-33.
36. Novick RP, Geisinger E. Quorum sensing in staphylococci. Annu Rev Genet 2008;42:541-64.
37. Boles BR, Horswill AR. Agr-mediated dispersal of Staphylococcus aureus biofilms. PLoS Pathog 2008; 4:e1000052.
38. Lauderdale KJ, Malone CL, Boles BR, Morcuende J, Horswill AR. Biofilm dispersal of community-associated methicillin-resistant Staphylococcus aureus on orthopedic implant material. J Orthop Res 2009; 28:55-61.
39. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42:186-91.
40. Skindersoe ME, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52:3648-63.
41. Starner TD, Shrout JD, Parsek MR, Appelbaum PC, Kim G. Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. Antimicrob Agents Chemother 2008; 52:137-45.
42. Fujimaki K, Ikeda Y, Takahata M, Yasuda T. Characteristics of biofilm formed by Pseudomonas aeruginosa in vitro. Chemotherapy (Tokyo) 1992; 40:886-93.
43. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T. Interaction between Biofilms Formed by Pseudomonas aeruginosa and Clarithromycin. Antimicrob Agents Chemother 1993; 37:1749-55.
44. Rachid S, Ohlsen K, Witte W, Hacker J, Ziebuhr W. Effect of subinhibitory antibiotic concentrations on polysaccharide intercellular adhesion expression in biofilm-forming Staphylococcus epidermidis. Antimicrob Agents Chemother 2000; 44:3357-63.
45. Wang Q, Sun FJ, Liu Y, Xiong LR, Xie LL, Xia PY. Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBCpositive and -negative clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother 2010; 54:2707-11.
46. Sano M, Hirose T, Nishimura M, Takahashi S, Matsukawa M, Tsukamoto T. Inhibitory action of clarithromycin on glycocalyx produced by MRSA. J Infect Chemother 1999; 5:10-5.
47. Presterl E, Hajdu S, Lassnigg AM, Hirschl AM, Holinka J, Graninger W. Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2009; 53:3205-10.
48. Abdi-Ali A, Mohammadi-Mehr M, Alaei YA. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27:196-200.
49. Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000; 44:1818-24.
50. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in, patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa - A randomized controlled trial. J Am Med Assoc 2003; 290:1749-56.
51. Fauroux B, Clement A, Tamalet A, Leroux E, Ravilly S, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006; 61:895-902.
52. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa A Randomized Controlled Trial. J Am Med Assoc 2010; 303:1707-15.
53. Wang R, Cai Y, Chai D, Bai N, Liang BB, Liu YN. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011; 66:968-78.
54. Herscu G, Wilson SE. Prosthetic infection: lessons from treatment of the infected vascular graft. Surg Clin North Am 2009; 89:391-401, viii.
55. von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 2005; 65:179-214.
56. Richards HK, Seeley HM, Pickard JD. Efficacy of antibiotic-impregnated shunt catheters in reducing shunt infection: data from the United Kingdom Shunt Registry. J Neurosurg Pediatr 2009; 4:389-93.
57. O'Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and meta-analysis of treatments for aortic graft infection. J Vasc Surg 2006; 44:38-45.
58. Huber TS, Carlton LM, O'Hern DG, et al. Financial impact of tertiary care in an academic medical center. Ann Surg 2000; 231:860-8.
59. Zeitler DM, Budenz CL, Roland JT, Jr. Revision cochlear implantation. Curr Opin Otolaryngol Head Neck Surg 2009; 17:334-8.
60. Yamasaki O, Akiyama H, Toi Y, Arata J. A combination of roxithromycin and imipenem as an antimicrobial strategy against biofilms formed by Staphylococcus aureus. J Antimicrob Chemother 2001; 48:573-7.
61. Furuhata M, Iwamura M, Baba S, Inoue M. Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty. Int J Urol 2003; 10:228-30.
62. Peck KR, Kim SW, Jung SI, et al. Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis. Chemotherapy 2003; 49:189-93.